Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Apathy and Manifestations of a Wide Variety of Neuropsychiatric Disorders in Patients with Parkinson's Disease

Version 1 : Received: 7 June 2021 / Approved: 9 June 2021 / Online: 9 June 2021 (11:14:07 CEST)

How to cite: Huseyn, E. Apathy and Manifestations of a Wide Variety of Neuropsychiatric Disorders in Patients with Parkinson's Disease. Preprints 2021, 2021060259. https://doi.org/10.20944/preprints202106.0259.v1 Huseyn, E. Apathy and Manifestations of a Wide Variety of Neuropsychiatric Disorders in Patients with Parkinson's Disease. Preprints 2021, 2021060259. https://doi.org/10.20944/preprints202106.0259.v1

Abstract

Apathy in patients with Parkinson's disease (PD) is one of the least studied manifestations of a wide range of neuropsychiatric disorders (PND). The frequency of apathy in PD, according to various researchers, is 17–80%. Structural and neurochemical changes associated with PD are considered as the leading pathophysiological factors of apathy. Possible general pathophysiological mechanisms of apathy and hypokinesia, depression, executive (frontal) cognitive functions, sleep disorders in PD are discussed. The basis of the pathophysiological commonality of apathy, hypokinesia, and executive functions is probably bilateral disturbances in the functional connections of the stratum and dorsolateral, medial parts of the prefrontal cortex. The combination of apathy and depression in PD may be due to dysfunction of the structures of the limbic system and the medial orbital prefrontal cortex responsible for motivational determined behavior. The variability of the relationship between apathy and hypokinesia, depression, cognitive impairments, sleep disorders at different stages of PD may be associated with the phenomenological heterogeneity of apathy.Apathy worsens the quality of life, makes a significant contribution to disorders of both household and social adaptation of PD patients. It is promising to study the possibility of correcting apathy using dopaminergic therapy. Against the background of the appointment of pramipexole (1.5-3.0 mg / day) to 20 patients with PD (middle stage, according to Hen-Yar-2.5) to correct movement disorders after 4-6 weeks of therapy, a statistically significant positive dynamics of apathy were noted. According to the total assessment of the scale of apathy SE Starkstein (AS). As a result of the study, no statistically significant correlation was found between the dynamics of the total apathy indicator and the dynamics of motor symptoms of PD according to the unified rating scale for assessing PD (“Motor functions”), which, we believe, indicates an independent effect of pramipexole therapy in relation to motivational disorders.

Keywords

Deep Learning (DP); Parkinson's disease (PD); Multiple System Atrophy (MSA); Magnetic Resonance Imaging (MRI); Neural Network (NN)

Subject

Medicine and Pharmacology, Immunology and Allergy

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.